Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
Leonardo Augusto Luvison AraújoSabrina Esteves de Matos Almeida

Abstract

Entry inhibitors are a class of antiretroviral (ARV) drugs that prevent HIV replication by blocking viral entry into the host cell. The investigation of naturally occurring mutations associated with entry inhibitors across subtypes is required because genetic differences between HIV-1 variants may influence the emergence of drug resistance. Despite the importance of subtype C, which predominates globally, the majority of studies include only subtype B strains. To investigate the presence of natural resistance mutations to entry inhibitors in HIV-1 subtypes B, C, and CRF31_BC strains. Eighty samples were collected from antiretroviral-naïve patients. The gp41 gene from 67 patients and the gp120 gene from 65 patients were partially sequenced. Resistance mutations to entry inhibitors Enfuvirtide, Maraviroc, and Vicriviroc were screened. ENF resistance-associated mutations of HR1 and HR2 on gp41 were not associated with any subtype. However, the major polymorphisms detected in HR1: N42S, L54M, and A67T were most prevalent in subtype C (p<0.001). Mutations A316T and R315Q in gp120, which are related to MVC and VCV reduced susceptibility respectively, were predominant in subtype C (p<0.05). This study shows that many more resistance-a...Continue Reading

References

Dec 19, 2002·AIDS Research and Human Retroviruses·Monick Lindenmeyer GuimarãesUNKNOWN Brazilian Network for HIV Isolation and Characterization
Jul 2, 2003·Nature Medicine·Roger J Pomerantz, David L Horn
Jul 30, 2003·Journal of Virology·Hector R RangelMiguel E Quiñones-Mateu
Apr 13, 2004·AIDS·Guowei FangHarold Burger
Jul 3, 2004·The Journal of Antimicrobial Chemotherapy·Michael L Greenberg, Nick Cammack
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·Stefano MenzoMassimo Clementi
Feb 22, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·R CarmonaR Nájera
Dec 24, 2005·Current Opinion in Infectious Diseases·Anna Maria Geretti
Aug 30, 2008·AIDS·Gonzalo BelloMariza G Morgado
Apr 3, 2009·Current Opinion in HIV and AIDS·John P Moore, Daniel R Kuritzkes
May 23, 2009·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Caroline Pereira Bittencourt PassaesMonick Lindenmeyer Guimarães
Aug 3, 2010·PloS One·Elcio Leal, Fabiola E Villanova
Feb 10, 2011·Journal of Translational Medicine·Bruce L GilliamRobert R Redfield
Aug 13, 2011·Journal of Medical Virology·Rúbia Marília de MedeirosSabrina Esteves Matos Almeida
May 1, 2010·Viruses·Michael A LobritzEric J Arts
Dec 2, 2011·PloS One·Dennis Maletich JunqueiraSabrina Esteves de Matos Almeida

❮ Previous
Next ❯

Citations

Nov 6, 2013·AIDS Research and Human Retroviruses·Nália IsmaelAmilcar Tanuri
Sep 17, 2013·Memórias do Instituto Oswaldo Cruz·Dennis Maletich JunqueiraSabrina Esteves de Matos Almeida
Feb 8, 2013·Viruses·Leonardo Augusto Luvison Araújo, Sabrina E M Almeida
Jul 12, 2013·ISRN Microbiology·Maria Mercedes Santoro, Carlo Federico Perno
Jul 3, 2013·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Hongyan GuoXiaohong Kong
Feb 9, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Joanna Smoleń-DzirbaAnd The Cascade Collaboration In EuroCoord

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.